A Scientific and Business Advisory Council will guide the establishment of the therapeutic strategies and ensure that TAP’s investments in various drug and device therapy projects is fiscally sound.

• Michaela Griggs
• Rodney A. Hedeen
• Albert W. Leland
• Albert (Ab) Rees
• Kevin Robie

Michaela is a fast-tracked successful multi-national and global health-care business leader with over 20 years of experience of delivering creative marketing solutions, transforming consumer and healthcare professionals' behaviour and loyalty and driving business growth. Michaela has leveraged her clinical/scientific background to translate complex scientific information into easily-understood positioning and messaging to multiple audiences, and utilizes her classic marketing skill-set to drive scientific-based brand appeal to a broad consumer base. Michaela has consistently introduced 'best–in-class' marketing and sales communication programs resulting in competitive advantage and product differentiation in highly complex life-sciences markets, including device, consumer (OTC) and pharmaceutical (Rx).

Currently, Michaela is the Global Head of Marketing and Business Development at 3M Unitek based in Southern California. Her prior leadership roles have included VP of US Marketing for Bayer Diabetes Care where she led a team of 40+ marketing, consumer promotion, trade marketing and 70 call-centre professionals, developing and implementing the long and short-term strategic marketing, sales and financial plans for Bayer Diabetes portfolio and Vice President, Global Strategic Business Unit – Cardiovascular Aspirin Portfolio; where Michaela was the global leader for both the Rx and OTC divisions of Bayer HealthCare for Bayer ®Aspirin (low dose) with responsibility for the development and global rollout of Bayer’s Cardio Aspirin strategies, marketing programs, new products and medical & clinical activities. Prior to that Michaela has been the marketing lead for several well know brand such as Bayer® Aspirin, One-A-Day®, Flintstones®, Bactine® and the Campho-phenique®. Michaela started her career as an orthoptist for the British National Health Service (NHS)

Back to List | Back to Top

Mr. Hedeen is a seasoned business leader having held numerous senior-level positions in manufacturing and management within several large companies. He is well versed in all aspects of business with a particular reputation for driving positive business results. Most recently Mr. Hedeen was president of Relizon, a leader in documents, CRM solutions, digital printing and document management services that was sold by the Carlyle Group in 2005. After the sale of Relizon, Mr. Hedeen elected to retire.

Back to List | Back to Top

Mr. Leland has held senior-level positions with many large financial institutions. Since leaving the corporate banking industry, Mr. Leland has become a highly sought after financial and business advisor to many significant family trusts.

Back to List | Back to Top

Click here to see comments for Mr. Rees under Board of Directors.

Back to List | Back to Top

Mr. Robie is Vice President of Portfolio Management for Soin International and is responsible for providing strategic management, acquisition diligence, administrative support and financial services to the Soin International portfolio of businesses.

Mr. Robie began his career in 1981 with The Reynolds & Reynolds Company in Dayton, Ohio holding several senior level positions for more than 20 years. In 2001, Mr. Robie was named Vice President of Marketing for The Relizon Company, an $800 million document management and business process outsourcing provider.

Mr. Robie holds a bachelor's degree in marketing from the University of Dayton and a master's degree in business administration with a concentration in marketing and finance also from the University of Dayton.

Mr. Robie currently holds the position of President and Treasurer on the Board of Directors for two National Heritage Academy Charter Schools in Dayton, Ohio. National Heritage Academy owns and operates over 50 charter schools nationwide. Mr. Robie serves as Board Trustee for The Entrepreneurs Center, an incubator for technology enterprises.

Back to List | Back to Top

James D. Crapo, M.D., is Professor of Medicine at National Jewish Health and the University of Colorado Health Sciences Center in Denver, Colorado. He served as Executive Vice President of Academic Affairs and Chair of the Department of Medicine at National Jewish from 1996 to 2004. Dr. Crapo received his M.D. from the University of Rochester. Prior to moving to National Jewish in 1996, Dr. Crapo spent over 15 years as Chief of the Pulmonary and Critical Care Medicine Division at Duke University Medical Center. Throughout his professional career he has been active in numerous professional societies, including service on the National Institutes of Health's National Heart, Lung, and Blood Institute Board of Extramural Advisors and serving as President of the American Thoracic Society. Dr. Crapo maintains a large research program focused on the role of oxidants and antioxidants in the causation and treatment of diseases. He specializes in Chronic Obstructive Pulmonary Disease (COPD), Alpha-1 Antitrypsin Deficiency, Chronic Cough, and Emphysema. Dr. Crapo is Board Certified by the American Board of Internal Medicine and the American Board of Pulmonary Diseases.

Back to List | Back to Top

Dr. Flotte is Dean of the School of Medicine and Executive Deputy Chancellor of the University of Massachusetts Medical School (UMMS). In these roles, Dr. Flotte serves UMMS as chief academic and administrative officer of the School of Medicine, overseeing all academic activities of the basic and clinical science departments, including education and research for the School of Medicine and the Graduate School of Biomedical Sciences. Dr. Flotte joined the Medical School in May 2007 from the University of Florida (UF), where he was the Nemours Eminent Scholar and Chair of the Department of Pediatrics for the College of Medicine.

Dr. Flotte received his undergraduate degree in the biological sciences from the University of New Orleans in 1982, and his medical degree from the Louisiana State University School of Medicine in 1986. After serving his residency in pediatrics at Johns Hopkins University, he completed a pediatric pulmonary fellowship and postdoctoral training in molecular virology there in 1992.

In 1996 Dr. Flotte joined the faculty of the University of Florida and was appointed Associate Director of UF’s Powell Gene Therapy Center. In 2000 he was named Director of the Powell Center and founding Director of the newly established UF Genetics Institute, a cross-campus multidisciplinary unit encompassing gene therapy, human genetics, agricultural genetics and comparative genomics. In 2002 he stepped down from these roles to accept the position of Chair of the Department of Pediatrics.

An internationally known pioneer in human gene therapy, he is currently investigating the use of gene therapy for genetic diseases that affect children, mainly cystic fibrosis.

He is the author of more than 130 scholarly papers and his research has been funded by the National Institutes of Health, the Cystic Fibrosis Foundation and the Juvenile Diabetes Research Foundation.

He is a member of the American Society for Gene Therapy and the American Society of Microbiology, among many other professional associations.

Back to List | Back to Top

Dr. Lomas graduated from the University of Nottingham in 1985 and then worked in Nottingham and Birmingham as a junior hospital doctor in General and Respiratory Medicine. He moved to Cambridge as an MRC Training Fellow to undertake his Ph.D. and then secured a second fellowship as an MRC Clinician Scientist. In 1994 he was appointed as University Lecturer at the University of Cambridge and in 1998 was appointed to the Professorship of Respiratory Biology. He has been an Honorary Consultant Respiratory Physician at Addenbrooke’s and Papworth Hospitals since 1994 and has a particular interest in Alpha-1 Antitrypsin Deficiency, the serpinopathies and COPD.

In 2008, at the Alpha-1 Association's 17th Annual National Educational Conference, Dr. Lomas received the Advancement of Research Award for his profound impact in Alpha-1 research. He currently serves as the Chair of the Alpha-1 Foundation’s Grants Advisory Committee (GAC) and also serves as a member on the Medical and Scientific Advisory Committee (MASAC).

Back to List | Back to Top

Click here to see comments for Mr. McCormick under Board of Directors.

Back to List | Back to Top

Dr. McElvaney is Chairman of and Professor of Medicine in the Respiratory Research Division of the Royal College of Surgeons in Dublin, Ireland. Dr. McElvaney received his medical education at the University College Dublin and completed his postgraduate medical education at the Mater Misericordiae Hospital and the Mater St. Laurence Hospital both in Dublin.

Dr. McElvaney's unit has a well-established track record in research into Cystic Fibrosis and their work on lung defenses has led to interactions with pharmaceutical companies interested in translational research. For example, in 1999 Beaumont Hospital was the first site worldwide for intravenous administration of transgenic alpha-1 antitrypsin to individuals with Alpha-1 Antitrypsin Deficiency. In 2003 Dr. McElvaney founded the Alpha One Foundation of Ireland and subsequently received funding from the Department of Health and Children to set up an Alpha-1 research unit to further research into the condition. He also established the first targeted detection program and registry for individuals with Alpha-1 in Europe.

Back to List | Back to Top

Jon F. Merz is Associate Professor and Associate Chair for Faculty Affairs in the Department of Medical Ethics in the School of Medicine, Senior Fellow in the Center for Bioethics; and an Associate Scholar in the Center for Clinical Epidemiology and Biostatistics, at the University of Pennsylvania. He holds a B.S. in Nuclear Engineering from Rensselaer Polytechnic Institute, an M.B.A. from the University of North Florida, a J.D. from Duquesne University, and a Ph.D. in Engineering and Public Policy from Carnegie Mellon University. Dr. Merz has established research expertise in the areas of research ethics, biobanking and genetics research, and gene patenting. Since 2003, Dr. Merz has managed the IRB Forum, a moderated discussion forum focused on theoretical and practical research ethics oversight issues. Dr. Merz's seminal empirical work on the ethics and public policy of gene patenting has been cited in support of proposed federal legislation as well as by national policy committees in Canada, the UK, and France, as well as by the Organisation for Economic Co-operation and Development (OECD). He has provided testimony on these issues to both the Department of Health and Human Services (DHHS) Secretary's Advisory Committee on Genetic Testing as well as the US House of Representatives.

He is a member of the American Association for the Advancement of Science and the American Society for Bioethics and Humanities, and he served in 2001-2002 as an at-large member of the American Bar Association Coordinating Group on Bioethics and the Law.

Back to List | Back to Top

Dr. Rennard is Larson Professor of Medicine in the Pulmonary and Critical Care Medicine Section of the Department of Internal Medicine at the University of Nebraska Medical Center in Omaha, Nebraska, and courtesy professor of the Department of Pathology and Microbiology and the Department of Genetics, Cell Biology and Anatomy. He received a B.A., with honors in Folklore and Mythology from Harvard University and a doctor in medicine degree with honors from the Baylor College of Medicine, Houston, Texas. He completed internal medicine training at Barnes Hospital, Washington University, St. Louis, Missouri and trained in pulmonary diseases at the National Institutes of Health where he remained for seven years, conducting research in the cell biology of lung disease. He joined the University of Nebraska Medical Center in 1984 as Chief of Pulmonary and Critical Care, a position he retained until 1997. He was the director of the Nebraska Office of Tobacco Control and Research from 1997 until 2008.

Dr. Rennard currently serves on the Board of Directors of the COPD Foundation and the Alpha-1 Foundation. He is a member of the American Thoracic Society committee on corporate relations and the National Heart Lung education program executive committee. Dr. Rennard is active in several professional societies and has previously served on the Board of Directors for the American Thoracic Society, the Council of the American Lung Association and was a governor for the American College of Chest Physicians. He served on the American Board of Internal Medicine, pulmonary section and was a member of the expert panel which prepared the global GOLD guidelines for Chronic Obstructive Pulmonary Disease for the World Health Organization/National Heart, Lung and Blood Institute. He has served on several task force committees, including an American Thoracic Society/European Respiratory Society task force that prepared the society's joint COPD standards.

He maintains an active program of clinical investigation in COPD and smoking cessation and a program of basic research in the mechanisms of lung tissue repair and remodeling, including the role of stem cells in disease pathogenesis and repair.

Back to List | Back to Top

Dr. Silverman is Associate Professor of Medicine at Harvard Medical School and Associate Physician at Brigham & Women’s Hospital-Channing Laboratory Pulmonary and Critical Care Division. Dr. Silverman received his M.D. and Ph.D. from Washington University School of Medicine in 1990. His research focuses on the genetic epidemiology of Chronic Obstructive Pulmonary Disease (COPD) and asthma, combining field, laboratory and analytical approaches to address the challenging problems involved in elucidating the genetic influences in complex diseases. Dr. Silverman is currently the principal investigator of a collaborative study to identify genetic modifiers of severe Alpha-1 Antitrypsin Deficiency funded by the National Institutes of Health. He is also the principal investigator at one of the lead centers in a 5-year collaborative study of COPD genetics titled the COPD Gene Study. In the past several years, he has served as a co-investigator on a variety of new family-based association studies of the genetics of asthma, including the Childhood Asthma Management Program Genetics Ancillary Study, the Genetics of Latino Americans Study, and a study of the genetics of asthma in Costa Rica.

His clinical work at Brigham and Women’s Hospital (BWH) in the Center for Chest Diseases has served to sharpen his understanding of relevant phenotypes for use in genetic investigations. In the past two years, he has worked to start a COPD center at BWH to improve and coordinate clinical care of COPD patients at BWH. Dr. Silverman is a member of the Alpha-1 Foundation’s Board of Directors as well as the Chair of the Foundation’s Medical and Scientific Advisory Committee. Dr. Silverman also serves on the Foundation’s Tissue Bank Advisory Committee, Grants Advisory Committee, Epidemiology and Detection Working Group and the Scientific Honors Advisory Committee.

Back to List | Back to Top

Dr. Stockley is Professor of Medicine at Birmingham University and Medical Director of the Lung Resource Centre, Queen Elizabeth Hospital, Birmingham. He is Director of Research and Development for the University Hospital Birmingham NHS Foundation Trust. He is a member of the British Thoracic Society, European Respiratory Society and American Thoracic Society. He is also a section head for COPD & Allied Disorders, part of the Respiratory Disorders faculty. His area of specialty is the pathogenesis of COPD. His work has received grants from British Lung Foundation, UBH Endowment Fund and a non-commercial program grant from Bayer. He is also an Associate Editor of The Respiratory Research Journal.

Dr. Stockley has a longstanding interest in COPD with special reference to airway inflammation, proteinases and anti-proteinases, and especially the role of the neutrophils, bacteria and exacerbations. His research focuses on investigating the factors governing neutrophil differentiation, activation and recruitment as processes that determine the degree of tissue damage resulting in the establishment and progression of chronic lung disease.

Back to List | Back to Top

Dr. Teckman is Director of Gastroenterology and Hepatology at Cardinal Glennon Children's Medical Center in Saint Louis, Missouri. He has been involved in research on Alpha-1 Antitrypsin Deficiency, and other liver diseases for 15 years, and has served as a volunteer and patient educator for the American Liver Foundation and the Alpha-1 Foundation. Research in Dr. Teckman's laboratory has included insights into the mechanisms of cellular damage within the liver, as well as human therapeutic drug trials.

Dr. Teckman's work has been recognized with awards for research, patient care, and service, including the Miles and Shirley Fiterman Basic Research Award in Gastroenterology and Best Doctors in America. Dr. Teckman has served as a consultant to the pharmaceutical industry for projects on drug safety and drug development, and has been involved in patient advocacy for genetic disease anti-discrimination efforts.

Back to List | Back to Top

Dr. Trapnell is Director of Cincinnati Children’s Hospital’s Cystic Fibrosis Therapeutics Development Network Center, Assistant Director of the Adult Cystic Fibrosis Care Center, Director of the Rare Lung Diseases Clinical Research Consortium, and Scientific Director of the Pulmonary Alveolar Proteinosis Foundation.

Dr. Trapnell received his M.D. from the University of Maryland in 1985, and completed a medical residency at The Ohio State University Hospitals and a fellowship in pulmonary medicine at the Clinical Center of the National Institutes of Health (NIH), where he then served as senior attending physician. Subsequently, he established the Division of Pulmonary and Virology Studies at Genetic Therapy, Inc., a subsidiary of Novartis, Pharmaceuticals, serving as Vice President before joining Cincinnati Children’s Hospital Medical Center, where he is now professor. Dr. Trapnell is also a former Scientific Director of the Alpha-1 Foundation, for which he organized and directed the grants program for eight years.

Dr. Trapnell has conducted research in the field of lung disease since his early medical training and has been continuously funded by the NIH since 2001. He has published over 90 original articles and has trained more than 16 post-doctoral fellows. Dr. Trapnell’s research interests are focused to the pathogenesis and therapy of rare lung diseases and mechanisms by which GM-CSF regulates innate immunity and lung host defense.

Back to List | Back to Top

Dr. Tuder is currently the Hart Family Professor of Medicine and director of the program in translational lung research at the University of Colorado Denver, School of Medicine. He received his M.D. in 1979 and completed his pathology residency at São Paulo University, School of Medicine. After completing a post-doctoral fellowship at Stanford University, he worked as both an attending pathologist and medical supervisor at University Hospital in São Paulo, Brazil. He then moved to the University of Colorado Health Sciences Center where he worked as Instructor, Assistant Professor, and Associate Professor. In 2001 he accepted a position as an Associate Professor of Medicine and Pathology, and Director of the Division of Cardiopulmonary Pathology at Johns Hopkins University. In 2003 he was promoted to the position of Professor of Pathology and Medicine and continued to lead the Department of Cardiopulmonary Pathology. In 2008 he returned to the University of Colorado Denver, School of Medicine and his current appointment.

Dr. Tuder serves as Chair of the Alpha-1 Foundation’s DNA & Tissue Bank Advisory Committee and is a member of the Medical and Scientific Advisory Committee and the Grants Advisory Committee. He is a founding member and senior fellow of the Pulmonary Vascular Research Institute. He is currently on the Editorial Board of the Journal of Cell Death and he is a member of the Respiratory Disorders Faculty of the Faculty of 1000 Medicine.

Dr. Tuder’s research has included: focus on defining the mechanisms of COPD pathogenesis, exploring the molecular, cellular, and histopathological features of Pulmonary Hypertension, studies of the pathogenesis of cigarette smoke induced emphysema and its underlying mechanisms, including the role of RTP-801 and adipocytokine, as well as his investigation in the pathogenesis of schistosomiasis-related pulmonary hypertension.

Back to List | Back to Top

Dr. Adam Wanner serves as the Scientific Director of the Alpha-1 Foundation as well as a Joseph Weintraub Professor of Medicine at the University of Miami (UM) School of Medicine. Dr. Wanner is a graduate from the University of Basel School of Medicine in Switzerland. He completed his residency at the Kantonsspital in Switzerland and the Philadelphia General Hospital in Pennsylvania. Dr. Wanner also completed a pulmonary fellowship at the Mount Sinai Medical Center in Miami Beach, Florida. He began employment in the pulmonary department at the University of Miami Miller School of Medicine in 1973. He quickly climbed through the ranks at UM, serving as Chief of Pulmonary/Critical Care division, directing the Pulmonary/Critical Care Fellowships and serving as the Vice Chair of Research in the Department of Medicine. Dr. Wanner effectively balances research with teaching, patient care and service to the community. He has had over 200 original research papers published and has written over 40 book chapters and review articles. Dr. Wanner has been active on a number of editorial boards, and has served on and chaired several NIH study sections. He has chaired the Veteran's Association (VA) Merit Review Board for Pulmonary Disease and has had uninterrupted federal grant support for the past 30 years. Dr. Wanner also served as the President of the American Thoracic Society from 2001-2002.

Back to List | Back to Top

Dr. Zern is a doctor of internal medicine who specializes in Hepatology. He is affiliated with the University of California (UC) Davis Health System of Sacramento California. He graduated from Harvard University School of Medicine in 1975, and has contributed over 88 publications within his field.

Dr. Zern is Director of Transplant Research at UC Davis Medical Center. There, Dr. Zern is one of about a dozen researchers currently investigating stem cells. He is also trying to identify the best medium for stimulating stem cell self-renewal and differentiation, and studying the potential for using these cells to create a liver dialysis system that could act as an artificial liver. Another of Dr. Zern's research projects explores the use of stem cells in the development of bio-artificial organs.

Dr. Zern has served on the Alpha-1 Foundation’s Grants Advisory Committee since its inception. Prior to this date he was the recipient of a Fernandez Liver Initiative Grant from the Alpha-1 Foundation.

Back to List | Back to Top

For more information on The Alpha-1 Project, contact us at: info@thealpha-1project.com.